GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $8.38 Consensus Target Price from Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $8.38.

GDRX has been the subject of several analyst reports. Mizuho initiated coverage on shares of GoodRx in a research report on Wednesday, December 4th. They issued a "neutral" rating and a $5.00 target price for the company. KeyCorp lowered their price objective on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Citigroup lowered their price objective on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a research report on Friday, January 10th. Barclays lowered their price objective on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a research report on Monday, November 11th. Finally, Morgan Stanley lowered their price objective on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a research report on Tuesday, December 17th.

GoodRx Price Performance

Shares of NASDAQ:GDRX traded up $0.20 during midday trading on Monday, hitting $5.03. The stock had a trading volume of 607,560 shares, compared to its average volume of 1,073,885. The company's 50-day moving average price is $4.65 and its 200-day moving average price is $6.00. The company has a market capitalization of $1.92 billion, a P/E ratio of -167.67, a price-to-earnings-growth ratio of 2.44 and a beta of 1.28. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx has a fifty-two week low of $4.09 and a fifty-two week high of $9.26.

Institutional Trading of GoodRx

Large investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC bought a new position in GoodRx during the third quarter worth about $33,000. National Bank of Canada FI boosted its position in GoodRx by 34.9% during the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock worth $39,000 after purchasing an additional 2,151 shares during the period. RPO LLC bought a new position in GoodRx during the fourth quarter worth about $52,000. Versor Investments LP bought a new position in GoodRx during the fourth quarter worth about $54,000. Finally, Verus Capital Partners LLC bought a new position in GoodRx during the fourth quarter worth about $55,000. Hedge funds and other institutional investors own 63.77% of the company's stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.